Fintepla (fenfluramine) is a prescription drug used to treat seizures from certain epilepsy conditions. Fintepla can cause side effects that range from mild to serious. Examples include diarrhea and ...
How Does Fintepla Work for Seizures? Seizures are caused by sudden electrical activity changes in the brain. These changes are temporary but result in changes in movement, behavior, sensation, or ...
Fintepla (fenfluramine) is an oral solution used to treat seizures from certain epilepsy conditions. It’s typically taken twice daily. Specific doses are based on body weight and calculated by your ...
FINTEPLA® has demonstrated efficacy in the most difficult-to-treat seizure types,1,2 including drop seizures, which cause a person to suddenly lose muscle tone, become limp, and fall to the ground, ...
UCB plans to file for regulatory approval of Fintepla to treat a third epileptic condition “as soon as possible,” the company said, as it reported results of a phase 3 trial in patients with the ultra ...
Zogenix Inc (NASDAQ: ZGNX) has announced new data showing the positive impact of treatment with Fintepla (fenfluramine) on everyday executive function for children and young adults with Lennox-Gastaut ...
ATLANTA, June 24, 2024 /PRNewswire/ -- UCB, a global biopharmaceutical company, today announced that Epilepsia published findings from a comprehensive scoping review examining the efficacy of ...
The approval was based on data from a phase 3 trial that evaluated the efficacy and safety of Fintepla in 263 patients aged 2 to 35 years with LGS. The Food and Drug Administration (FDA) has approved ...
Oral solution approved to treat seizures associated with Dravet syndrome The European Commission (EC) has approved Zogenix’s Fintepla (fenfluramine) for the treatment of seizures associated with ...
UCB’s Fintepla (fenfluramine) has been associated with a nearly 50% reduction in countable motor seizure frequency (CMSF) in adult and paediatric patients with cyclin-dependent kinase-like 5 (CDKL5) ...
As UCB works to secure U.S. approval for its promising plaque psoriasis prospect bimekizumab, the company has landed an FDA nod in a rare disease where it will challenge Jazz Pharmaceuticals. Fintepla ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results